<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SCUT-China_B_Crispri skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SCUT-China B/Crispri</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>IGEM-China_B</TITLE></P><DIV class="nav"><LI><A href="https://2016.igem.org/Team:SCUT-China_B">Home</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Overview">Project</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Overview">Overview</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Results">Achievements</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Judging">Judging</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Modeling">Modeling</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Apoptosis">Apoptosis</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Crispri">CRISPRi/a</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Notebook</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Protocol</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Safety">Safety</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Human Practice</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Overview</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/HP/HP1">Project Design</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/HP/HP2">Public Outreach</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/HP/HP3">Hospice Care</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Team">Lab</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Collaborations">Collaborations</A></LI><LI><A href="https://2016.igem.org/Team:SCUT-China_B/Attributions">Attributions</A></LI></DIV><DIV class="bar"><DIV class="Ltitle"><A href="">Overview</A></DIV><DIV class="Ltitle"><DIV class="Mtitle"><A href="">CRISPRi/a</A></DIV><DIV class="Stitle"><A href="">Model Formation</A></DIV><DIV class="Stitle"><A href="">Equations and Parameters</A></DIV><DIV class="Stitle"><A href="">Parameters Optimization</A></DIV></DIV><DIV class="Ltitle"><DIV class="Mtitle"><A href="#Tumor">Tumor Specific CRISPRa</A></DIV><DIV class="Stitle"><A href="">Model Formation</A></DIV><DIV class="Stitle"><A href="">Equations and Parameters</A></DIV></DIV><DIV class="Ltitle"><A href="">References</A></DIV></DIV><DIV class="article"><DIV class="section"><DIV><P>CRISPRi/a</P><P>CRISPRi: bcl-2 repression</P><P>CRISPRi is to use dCas9-KRAB to block the RNA polymerase transcription elongation and initialization. We till several sgRNAs or single sgRNA in the bcl-2 promoter to obtaion optimal repression. We create the CRISPRi model with mass action laws in order to gain fold repression of bcl-2</P><P>CRISPRa: bax activation </P><P>CRISPRa is to use dCas9-VP64 to activate the transcription initialization. We use the similar stragegy to obtain optimal activation. And we create CRISPRa model with mass action laws in order to gain fold activation of bax.</P></DIV><DIV id="Tumor"><P>The tumor specific promoter in our project is with an ampilification system. It contains a minimal promoter targeted by three dCas9-VP64-sgRNA complex. We build a two-step-transcription-activation model to analyze whether it can promote enough dCas9-VP64.</P><P> We build up a model for tumor specific promoter that expresses the CRISPR/dCas9-VP96 system.</P><P>The dCas9-VP64-GFP expression rate under EF1α promoter, survivin promoter, and Bax_1 promoter.</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>